Menlo Therapeutics Inc. (42) | Uncategorized (12)
Recent Contracts
-
Offer Letter, dated as of March 7, 2022, by and between VYNE Pharmaceuticals Inc. and Iain Stuart
(Filed With SEC on March 17, 2022)
-
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934
(Filed With SEC on March 17, 2022)
-
Offer Letter, dated as of March 15, 2022, by and between VYNE Pharmaceuticals Inc. and Tyler Zeronda
(Filed With SEC on March 17, 2022)
-
Evaluation and Option Agreement, dated as of April 30, 2021, by and between In4Derm Limited and VYNE Therapeutics Inc
(Filed With SEC on November 10, 2021)
-
Offer Letter, dated as of June 7, 2021, by and between Tyler Zeronda and VYNE Pharmaceuticals Inc
(Filed With SEC on August 12, 2021)
-
Offer Letter, dated as of April 7, 2021, by and between Mutya Harsch and VYNE Pharmaceuticals Inc
(Filed With SEC on May 6, 2021)
-
Offer Letter, dated as of April 7, 2021, by and between Andrew Saik and VYNE Pharmaceuticals Inc
(Filed With SEC on May 6, 2021)
-
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934
(Filed With SEC on March 4, 2021)
-
Offer Letter, dated as of March 25, 2020, by and between Menlo Therapeutics Inc. and David Domzalski
(Filed With SEC on May 11, 2020)
-
Offer Letter, dated as of March 20, 2020, by and between Menlo Therapeutics Inc. and Andrew Saik
(Filed With SEC on May 11, 2020)
-
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934
(Filed With SEC on March 3, 2020)
-
Form of CSR Agreement
(Filed With SEC on November 12, 2019)